RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Khosrow Kashfi to Aspirin

This is a "connection" page, showing publications Khosrow Kashfi has written about Aspirin.
Connection Strength

9.744
  1. Firouzan B, Ghasemi R, Tetteh MT, Matson JB, Kashfi K. NOSH-aspirin (NBS-1120) attenuates motor defects and dopaminergic neuron degeneration in a rat model of Parkinson's disease. Eur J Pharmacol. 2025 Sep 05; 1002:177733.
    View in: PubMed
    Score: 0.865
  2. Chattopadhyay M, Nath N, Kodela R, Metkar S, Soyemi SA, Kashfi K. NOSH-aspirin (NBS-1120) inhibits estrogen receptor-negative breast cancer in?vitro and in?vivo by modulating redox-sensitive signaling pathways. J Pharmacol Exp Ther. 2025 Jan; 392(1):100019.
    View in: PubMed
    Score: 0.835
  3. Chattopadhyay M, Kodela R, Santiago G, Le TTC, Nath N, Kashfi K. NOSH-aspirin (NBS-1120) inhibits pancreatic cancer cell growth in a xenograft mouse model: Modulation of FoxM1, p53, NF-?B, iNOS, caspase-3 and ROS. Biochem Pharmacol. 2020 06; 176:113857.
    View in: PubMed
    Score: 0.600
  4. Kashfi K. Utility Of Nitric Oxide And Hydrogen Sulfide-Releasing Chimeras As Anticancer Agents. Redox Biol. 2015 08; 5:420.
    View in: PubMed
    Score: 0.450
  5. Vannini F, Kodela R, Chattopadhyay M, Kashfi K. NOSH-Aspirin Inhibits Colon Cancer Cell Growth: Effects Of Positional Isomerism. Redox Biol. 2015 08; 5:421.
    View in: PubMed
    Score: 0.450
  6. Kodela R, Chattopadhyay M, Vel?zquez-Mart?nez CA, Kashfi K. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid has enhanced chemo-preventive properties compared to aspirin, is gastrointestinal safe with all the classic therapeutic indications. Biochem Pharmacol. 2015 Dec 15; 98(4):564-72.
    View in: PubMed
    Score: 0.442
  7. Vannini F, Chattopadhyay M, Kodela R, Rao PPN, Kashfi K. Positional isomerism markedly affects the growth inhibition of colon cancer cells by NOSH-aspirin: COX inhibition and modeling. Redox Biol. 2015 Dec; 6:318-325.
    View in: PubMed
    Score: 0.439
  8. Vannini F, MacKessack-Leitch AC, Eschbach EK, Chattopadhyay M, Kodela R, Kashfi K. Synthesis and anti-cancer potential of the positional isomers of NOSH-aspirin (NBS-1120) a dual nitric oxide and hydrogen sulfide releasing hybrid. Bioorg Med Chem Lett. 2015 Oct 15; 25(20):4677-82.
    View in: PubMed
    Score: 0.439
  9. Nath N, Chattopadhyay M, Rodes DB, Nazarenko A, Kodela R, Kashfi K. Nitric Oxide-Releasing Aspirin Suppresses NF-?B Signaling in Estrogen Receptor Negative Breast Cancer Cells in Vitro and in Vivo. Molecules. 2015 Jul 09; 20(7):12481-99.
    View in: PubMed
    Score: 0.436
  10. Chattopadhyay M, Nath N, Kodela R, Sobocki T, Metkar S, Gan ZY, Kashfi K. Hydrogen sulfide-releasing aspirin inhibits the growth of leukemic Jurkat cells and modulates ?-catenin expression. Leuk Res. 2013 Oct; 37(10):1302-8.
    View in: PubMed
    Score: 0.381
  11. Kodela R, Chattopadhyay M, Goswami S, Gan ZY, Rao PP, Nia KV, Vel?zquez-Mart?nez CA, Kashfi K. Positional isomers of aspirin are equally potent in inhibiting colon cancer cell growth: differences in mode of cyclooxygenase inhibition. J Pharmacol Exp Ther. 2013 Apr; 345(1):85-94.
    View in: PubMed
    Score: 0.368
  12. Chattopadhyay M, Kodela R, Olson KR, Kashfi K. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model. Biochem Biophys Res Commun. 2012 Mar 16; 419(3):523-8.
    View in: PubMed
    Score: 0.344
  13. Chattopadhyay M, Kodela R, Nath N, Dastagirzada YM, Vel?zquez-Mart?nez CA, Boring D, Kashfi K. Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: a general property and evidence of a tissue type-independent effect. Biochem Pharmacol. 2012 Mar 15; 83(6):715-22.
    View in: PubMed
    Score: 0.341
  14. Chattopadhyay M, Kodela R, Nath N, Street CR, Vel?zquez-Mart?nez CA, Boring D, Kashfi K. Hydrogen sulfide-releasing aspirin modulates xenobiotic metabolizing enzymes in vitro and in vivo. Biochem Pharmacol. 2012 Mar 15; 83(6):733-40.
    View in: PubMed
    Score: 0.341
  15. Chattopadhyay M, Kodela R, Nath N, Barsegian A, Boring D, Kashfi K. Hydrogen sulfide-releasing aspirin suppresses NF-?B signaling in estrogen receptor negative breast cancer cells in vitro and in vivo. Biochem Pharmacol. 2012 Mar 15; 83(6):723-32.
    View in: PubMed
    Score: 0.341
  16. Chattopadhyay M, Velazquez CA, Pruski A, Nia KV, Abdellatif KR, Keefer LK, Kashfi K. Comparison between 3-Nitrooxyphenyl acetylsalicylate (NO-ASA) and O2-(acetylsalicyloxymethyl)-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (NONO-ASA) as safe anti-inflammatory, analgesic, antipyretic, antioxidant prodrugs. J Pharmacol Exp Ther. 2010 Nov; 335(2):443-50.
    View in: PubMed
    Score: 0.310
  17. Nath N, Chattopadhyay M, Kodela R, Tian S, Vlismas P, Boring D, Crowell JA, Kashfi K. Modulation of stress genes expression profile by nitric oxide-releasing aspirin in Jurkat T leukemia cells. Biochem Pharmacol. 2010 Jun 15; 79(12):1759-71.
    View in: PubMed
    Score: 0.300
  18. Nath N, Vassell R, Chattopadhyay M, Kogan M, Kashfi K. Nitro-aspirin inhibits MCF-7 breast cancer cell growth: effects on COX-2 expression and Wnt/beta-catenin/TCF-4 signaling. Biochem Pharmacol. 2009 Nov 15; 78(10):1298-304.
    View in: PubMed
    Score: 0.287
  19. Kashfi K, Rigas B. The mechanism of action of nitric oxide-donating aspirin. Biochem Biophys Res Commun. 2007 Jul 13; 358(4):1096-101.
    View in: PubMed
    Score: 0.248
  20. Kashfi K, Rigas B. Molecular targets of nitric-oxide-donating aspirin in cancer. Biochem Soc Trans. 2005 Aug; 33(Pt 4):701-4.
    View in: PubMed
    Score: 0.219
  21. Nath N, Labaze G, Rigas B, Kashfi K. NO-donating aspirin inhibits the growth of leukemic Jurkat cells and modulates beta-catenin expression. Biochem Biophys Res Commun. 2005 Jan 07; 326(1):93-9.
    View in: PubMed
    Score: 0.210
  22. Kashfi K, Borgo S, Williams JL, Chen J, Gao J, Glekas A, Benedini F, Del Soldato P, Rigas B. Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo. J Pharmacol Exp Ther. 2005 Mar; 312(3):978-88.
    View in: PubMed
    Score: 0.208
  23. Kashfi K, Rayyan Y, Qiao LL, Williams JL, Chen J, Del Soldato P, Traganos F, Rigas B, Ryann Y. Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect. J Pharmacol Exp Ther. 2002 12; 303(3):1273-82.
    View in: PubMed
    Score: 0.182
  24. Antoniou C, Xenofontos R, Chatzimichail G, Christou A, Kashfi K, Fotopoulos V. Exploring the Potential of Nitric Oxide and Hydrogen Sulfide (NOSH)-Releasing Synthetic Compounds as Novel Priming Agents against Drought Stress in Medicago sativa Plants. Biomolecules. 2020 01 10; 10(1).
    View in: PubMed
    Score: 0.149
  25. Lee M, McGeer E, Kodela R, Kashfi K, McGeer PL. NOSH-aspirin (NBS-1120), a novel nitric oxide and hydrogen sulfide releasing hybrid, attenuates neuroinflammation induced by microglial and astrocytic activation: a new candidate for treatment of neurodegenerative disorders. Glia. 2013 Oct; 61(10):1724-34.
    View in: PubMed
    Score: 0.095
  26. Chattopadhyay M, Goswami S, Rodes DB, Kodela R, Velazquez CA, Boring D, Crowell JA, Kashfi K. NO-releasing NSAIDs suppress NF-?B signaling in vitro and in vivo through S-nitrosylation. Cancer Lett. 2010 Dec 08; 298(2):204-11.
    View in: PubMed
    Score: 0.077
  27. Ouyang N, Williams JL, Tsioulias GJ, Gao J, Iatropoulos MJ, Kopelovich L, Kashfi K, Rigas B. Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model. Cancer Res. 2006 Apr 15; 66(8):4503-11.
    View in: PubMed
    Score: 0.057
  28. Gao J, Kashfi K, Liu X, Rigas B. NO-donating aspirin induces phase II enzymes in vitro and in vivo. Carcinogenesis. 2006 Apr; 27(4):803-10.
    View in: PubMed
    Score: 0.056
  29. Spiegel A, Hundley TR, Chen J, Gao J, Ouyang N, Liu X, Go MF, Tsioulias GJ, Kashfi K, Rigas B. NO-donating aspirin inhibits both the expression and catalytic activity of inducible nitric oxide synthase in HT-29 human colon cancer cells. Biochem Pharmacol. 2005 Oct 01; 70(7):993-1000.
    View in: PubMed
    Score: 0.055
  30. Gao J, Kashfi K, Rigas B. In vitro metabolism of nitric oxide-donating aspirin: the effect of positional isomerism. J Pharmacol Exp Ther. 2005 Mar; 312(3):989-97.
    View in: PubMed
    Score: 0.052
  31. Williams JL, Kashfi K, Ouyang N, del Soldato P, Kopelovich L, Rigas B. NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+)) mice. Biochem Biophys Res Commun. 2004 Jan 16; 313(3):784-8.
    View in: PubMed
    Score: 0.049
  32. Williams JL, Nath N, Chen J, Hundley TR, Gao J, Kopelovich L, Kashfi K, Rigas B. Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemoprevention. Cancer Res. 2003 Nov 15; 63(22):7613-8.
    View in: PubMed
    Score: 0.049
  33. Nath N, Kashfi K, Chen J, Rigas B. Nitric oxide-donating aspirin inhibits beta-catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear beta-catenin-TCF association. Proc Natl Acad Sci U S A. 2003 Oct 28; 100(22):12584-9.
    View in: PubMed
    Score: 0.048
  34. Jain S, Tran S, El Gendy MA, Kashfi K, Jurasz P, Vel?zquez-Mart?nez CA. Nitric oxide release is not required to decrease the ulcerogenic profile of nonsteroidal anti-inflammatory drugs. J Med Chem. 2012 Jan 26; 55(2):688-96.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support